New RT journal calls for papers

A Sneak Peek at 2025 ASCO From the GU Perspective

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.

May 14th 2025

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Roman Fabbricatore

May 14th 2025

FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Related Content

A Sneak Peek at 2025 ASCO From the GU Perspective

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

May 14th 2025